Michael U. Callaghan

Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A

Consensus definition of essential, optimal, and suggested components of a pediatric sickle cell disease center

Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection

The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies

Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study

Discussing investigational AAV gene therapy with hemophilia patients: A guide

ETV6 germline mutations cause HDAC3/NCOR2 mislocalization and upregulation of interferon response genes

Disulfiram (Antabuse) Activates ROS-Dependent ER Stress and Apoptosis in Oral Cavity Squamous Cell Carcinoma

Novel therapeutics for hemophilia and other bleeding disorders

Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial)

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

Celastrol induces apoptosis in hepatocellular carcinoma cells via targeting ER-stress/UPR

Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia

Induction of BCL2-Interacting Killer, BIK, is Mediated for Anti-Cancer Activity of Curcumin in Human Head and Neck Squamous Cell Carcinoma Cells

SMAD4 is a potential prognostic marker in human breast carcinomas